Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

Udo Holtick, MD PhD, Lukas P. Frenzel, MD, Shimabukuro-Vornhagen Alexander, MD, Sebastian Theurich, MD, Julia Claasen, Christof Scheid, MD, PhD, Michael von-Bergwelt-Baildon, MD PhD, Michael Hallek, MD PhD, Clemens Wendtner, MD, Jens M. Chemnitz, MD

Blood (2013) 122 (21): 4588.

https://doi.org/10.1182/blood.V122.21.4588.4588

Published: 2013

Journal Articles

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Sebastian Theurich, MD, Joke Malcher, Kerstin Wennhold, Alexander Shimabukuro-Vornhagen, MD, Jens M. Chemnitz, MD, Holtick Udo, MD, Anke Krause, MD, Carsten Kobe, MD, Deniz Kahraman, MD, Chakupurakal Geothy, Andreas Engert, MD PhD, Scheid Christof, MD, Michael Hallek, MD PhD, Michael von Bergwelt-Baildon, MD, PhD

Blood (2012) 120 (21): 4213.

https://doi.org/10.1182/blood.V120.21.4213.4213

Published: 2012

Journal Articles

Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4 + T cells

Sebastian Theurich, Joke Malcher, Hans J. Becker, Jens M. Chemnitz, Tanja M. Liebig, Alexander Shimabukuro-Vornhagen, Michael von Bergwelt-Baildon

Blood (2011) 118 (22): 5979–5980.

https://doi.org/10.1182/blood-2011-05-356683

Published: 2011

Journal Articles

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Bastian von Tresckow, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Denissa Peine, Stefan Knop, MD, Mariele Goebeler, MD, Jens M. Chemnitz, MD, Michael Hallek, MD, Andreas Engert, MD, Kai Hübel, MD

Blood (2011) 118 (21): 3965.

https://doi.org/10.1182/blood.V118.21.3965.3965

Published: 2011

Journal Articles

RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4 + T cells in Hodgkin lymphoma

Jens M. Chemnitz, Daniela Eggle, Julia Driesen, Sabine Classen, James L. Riley, Svenja Debey-Pascher, Marc Beyer, Alexey Popov, Thomas Zander, Joachim L. Schultze

Blood (2007) 110 (9): 3226–3233.

https://doi.org/10.1182/blood-2006-12-064360

Published: 2007

Includes: Supplemental data

Journal Articles

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.

Jens M. Chemnitz, James L. Riley, Kenneth A. Frauwirth, Inbal Braunstein, Sumire V. Kobayashi, Peter S. Linsley, Craig B. Thompson, Richard V. Parry

Blood (2004) 104 (11): 2657.

https://doi.org/10.1182/blood.V104.11.2657.2657

Published: 2004

NARROW

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4 + T cells

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4 + T cells in Hodgkin lymphoma

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.

Email alerts

ASH Publications

American Society of Hematology

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4 + T cells

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4 + T cells in Hodgkin lymphoma

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only